Leukemia, Myelogenous, Chronic, BCR-ABL Positive: all 982 studies
Page 6 of 10. Open to participants first (109), then studies with results posted, then the rest; newest registration first within each.
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
- Effect of Pharmacogenetics on Imatinib Plasma Level and ResponseCompletedNCT03262974
- The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous LeukaemiaStatus unknownNCT03241199Phase 2
- Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4logStatus unknownNCT03239886Not applicable
- Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT03228303Early Phase 1
- Low-dose Dasatinib as First-line Treatment for Chronic Myeloid LeukemiaStatus unknownNCT03216070Phase 4
- Myeloid Derived Suppressor Cells and Chronic Myeloid LeukemiaStatus unknownNCT03214718Not applicable
- Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML PatientsStatus unknownNCT03205267Phase 2
- KISS Study: Kinase Inhibition With Sprycel Start upActive, not recruitingNCT03193281Phase 2
- Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaStatus unknownNCT03131986
- ENDURE - Efficacy and Safety of AOP2014 With CML Patients in RemissionCompletedNCT03117816Phase 3
- Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia PatientsCompletedNCT03090477Not applicable
- Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
- Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid LeukemiaStatus unknownNCT03075969
- To Study the Impact of Stopping Therapy in Patients of CML With Molecular RemissionStatus unknownNCT03062436Not applicable
- Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United StatesCompletedNCT03045120
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in JordanCompletedNCT02977312
- Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic HarmonizationStatus unknownNCT02975115
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM StudyStatus unknownNCT02949570Phase 2
- Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSWithdrawnNCT02923986Phase 1/2
- 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patientsActive, not recruitingNCT02917720Phase 2
- National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First IntentWithdrawnNCT02903277
- A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CMLCompletedNCT02896842Phase 2
- Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid LeukemiaCompletedNCT02896829
- Preparatory Work to Assess Adherence to Oral ChemotherapyCompletedNCT02895542
- Dasatinib Holiday for Improved TolerabilityCompletedNCT02890784Phase 3
- Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803CompletedNCT02890758Phase 1
- Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL GeneStatus unknownNCT02885766Phase 1/2
- Vitro Study of Tigecycline to Treat Chronic Myeloid LeukemiaStatus unknownNCT02883036
- Regional Central Database Recording of Chronic Myeloid LeukemiaStatus unknownNCT02869256
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
- Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular ResponseCompletedNCT02852486Phase 2
- Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase InhibitorCompletedNCT02842333Not applicable
- Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)CompletedNCT02842320Not applicable
- Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedNCT02810990Phase 2
- Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous LeukemiaTerminatedNCT02795520Phase 1/2
- Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior TransplantationActive, not recruitingNCT02790515Phase 2
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid LeukemiaTerminatedNCT02782403Phase 1
- StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme MalignanciesWithdrawnNCT02765997Phase 2
- Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal TumorWithdrawnNCT02734823
- Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or NilotinibCompletedNCT02733445
- PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic MalignanciesCompletedNCT02730312Phase 1
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Allogeneic Stem Cell Transplantation for Children With CMLCompletedNCT02707393Phase 2/3
- Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT02689440Phase 2
- Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous LeukemiaStatus unknownNCT02687425Phase 2
- Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative DisordersWithdrawnNCT02663648
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs TherapyCompletedNCT02638467Phase 2
- Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCTTerminatedNCT02627573Phase 2
- Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
- Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic MalignanciesCompletedNCT02566395Phase 3
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter StudyCompletedNCT02546791
- DC Vaccination in CMLTerminatedNCT02543749Phase 1/2
- A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP PatientsStatus unknownNCT02511340Phase 2
- Safety And Efficacy Of BosutinibCompletedNCT02501330
- Allo-HSCT With Alternative Donor in Treatment of Hematologic MalignancyCompletedNCT02487069Not applicable
- Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)CompletedNCT02480608Phase 1/2
- An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®TerminatedNCT02455024
- Retrospective Evaluation of CML Patients in the National Compassionate ProgramTerminatedNCT02448095
- Radotinib as 3rd or Later Line Therapy in CP-CMLStatus unknownNCT02422719Phase 2
- Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)WithdrawnNCT02421926
- Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
- Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry StudyCompletedNCT02389972
- Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to DasatinibStatus unknownNCT02389920Phase 4
- Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
- Malaysia Stop Tyrosine Kinase Inhibitor TrialStatus unknownNCT02381379Phase 3
- Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare PopulationCompletedNCT02363868
- Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With DasatinibCompletedNCT02348957
- Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic MalignanciesStatus unknownNCT02338479
- Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
- Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaStatus unknownNCT02317159Phase 4
- Treatment-free Remission Accomplished With Dasatinib in Patients With CMLStatus unknownNCT02268370Phase 2
- Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic TransplantationNo longer availableNCT02258490
- Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsCompletedNCT02253277Phase 1
- Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral InfectionsTerminatedNCT02231853Phase 1
- Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell TransplantationCompletedNCT02226861Phase 1
- An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)TerminatedNCT02225574Phase 1
- Effect of 2nd Gen TKI in CMLCompletedNCT02222272
- Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative DisordersCompletedNCT02210858Phase 1/2
- A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML PatientsTerminatedNCT02204722Phase 4
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML PatientsCompletedNCT02201459Phase 3
- A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant PairsTerminatedNCT02200380Phase 2
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two YearsTerminatedNCT02174445Phase 3
- Allogeneic SCT for CML, TKI Failure After TKI FailureStatus unknownNCT02172365
- LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia PatientsStatus unknownNCT02164903
- Vascular Dysfunction and Antiangiogenic TherapyCompletedNCT02161978
- Population Pharmacokinetics of Imatinib in CML Patients in IranTerminatedNCT02146846
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
- Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous LeukemiaWithdrawnNCT02115672Phase 1/2
- Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2/3
- Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AMLActive, not recruitingNCT02091245Phase 1
- Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib TherapyTerminatedNCT02086487Phase 4
- A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLCompletedNCT02081378Phase 1